Drug Class: Proton-pump inhibitors
- Rabeprazole is a proton pump inhibitor (PPI) that covalently binds with and inactivates the gastric parietal cell proton pump (H+/K+-ATPase); in turn, inhibits gastric acid production and raises gastric pH.
- Shown to be more effective than first-generation PPIs in reducing the duration of nocturnal gastric acid breakthrough.
- Rabeprazole increased intragastric pH throughout the stomach with a rapid onset of action (within hours) and maintained an elevated pH through and between meals.
- Postprandial acid pockets, identified in the region of the cardia/gastro-oesophageal junction area postprandially, were decreased in number, length, and magnitude by rabeprazole.
- Gastric acidity
- Non-erosive reflux disease
- Erosive or ulcerative gastro-oesophageal reflux disease
- Active duodenal ulcer
- Eradication therapy of Helicobacter pylori